NCT06838273View on ClinicalTrials.gov

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

720

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Osimertinib

Oral administration, 80mg daily for a cycle of 3 weeks.

DRUG

Osimertinib

Oral administration, 80mg daily for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Shanghai East Hospital, Shanghai

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY